J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
This article was originally published in The Tan Sheet
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
You may also be interested in...
CEO Alex Gorsky says “20 key product launches” are planned for 2015, including extensions for the Listerine Healthy White mouthwash Neutrogena Hydro Boost skin care lines. Analgesics and upper respiratory products drive global OTC sales growth in the fourth quarter.
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.